Fresh From the Bench: Latest Federal Circuit Court Case
CASE OF THE WEEK
Roku, Inc. v. Universal Electronics, Inc., Appeal No. 2022-1058 (Fed. Cir. Mar. 31, 2023)
In this week’s Case of the Week, the Federal Circuit affirmed the U.S. Patent Trial and Appeal Board’s (PTAB’s) final written decision finding various claims had not been proven unpatentable as obvious. Appellee Universal Electronics’ U.S. Patent No. 9,716,853 (the ’853 patent) “relates to universal remotes and, more specifically, to a universal control engine (UCE) that facilitates communication between a controlling device (i.e., a remote) and intended target applications (e.g., a TV, a DVD player, a sounds system, etc.).”
Roku filed a petition for inter partes review of several claims of the ’853 patent, asserting the same would have been obvious in light of prior art references including a patent application to Chardon. The case turned on the narrow issue of whether Chardon discloses “a listing comprised of at least a first communication method and a second communication method different than the first communication method” as recited in each challenged claim. Roku argued that Chardon creates a database of command codes, “some of which are formatted for transmission according to a first communication method and some of which are formatted for transmission according to a second communication method.” As such, Roku argued Chardon meets the claimed limitations because it describes a listing of at least a first and a second communication method: “In its final written decision, the Board determined that Roku had not shown that the challenged claims would have been obvious.
By Annie White
ALSO THIS WEEK
Philip Morris Products S.A. v. International Trade Commission, Appeal No. 2022-1227 (Fed. Cir. Mar. 31, 2023)
The Federal Circuit affirmed a Section 337 decision by the International Trade Commission (“ITC”) barring the importation and sale of Philip Morris’s IQOS line of “heat-not-burn” tobacco products as infringing complainant R.J. Reynolds’ U.S. Patent Nos. 9,901,123 and 9,930,915. Of note were Philip Morris’s arguments concerning the Food and Drug Administration’s grant of pre-market and “modified-risk” tobacco product applications for the IQOS products, which implicated a determination that the products promoted public welfare insofar as they provided an aid in ceasing use of combustible cigarettes. The Federal Circuit rejected Philip Morris’s arguments that the ITC’s orders were against the public interest, finding that the ITC reasonably reviewed public interest evidence including FDA statements that the products still would be expected to cause some harm to individual consumers. The Court also found that the ITC satisfied its duty under 19 U.S.C. § 1337(b)(2) to “consult with” the Department of Health and Human Services (including FDA) by publishing a Notice of Investigation in the Federal Register, serving letters enclosing the Notice on HHS personnel, and considering information originating with FDA. The Court found that Philip Morris had forfeited any argument that the ITC should have done more by failing to raise it prior to a motion to stay the ITC’s orders pending the instant appeal.
The Court also rejected Philip Morris’s argument that R.J. Reynolds’ own VUSE and Solo products could not support the “domestic industry” requirement because they had not received FDA authorization at the time the complaint was filed with ITC; affirmed ITC’s determination that Philip Morris had not shown the asserted claims of the ’123 patent to be obvious; affirmed ITC’s determination that the ’915 patent was infringed; and affirmed ITC’s determination that evidence of an allegedly invalidating public use of the invention claimed in the ’915 patent was insufficiently corroborated. The Court thus affirmed the ITC’s decision in its entirety.
The opinion can be found here.
Edited by Nika Aldrich and Jason A. Wrubleski, Schwabe, Williamson & Wyatt, P.C.